| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Gene Link Inc is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners.
PrimeGen Biotech LLC is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vizgen is unlocking the power of spatial biomolecule profiling to bring new insight into biological systems and disease.